tert-Butyl 4-{2-[(cyclopropylmethyl)(methylsulfonyl) amino]phenyl}piperazinecarboxylate | 444582-33-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-Butyl 4-{2-[(cyclopropylmethyl)(methylsulfonyl) amino]phenyl}piperazinecarboxylate
• 英文别名: tert-Butyl 4-{2-[(cyclopropylmethyl)(methylsulfonyl)-amino]phenyl}piperazinecarboxylate；Tert-butyl 4-[2-[cyclopropylmethyl(methylsulfonyl)amino]phenyl]piperazine-1-carboxylate
• CAS: 444582-33-6
• 化学式: C₂₀H₃₁N₃O₄S
• 分子量: 409.55
• InChiKey: BZNHPPBUKKAOBD-UHFFFAOYSA-N

物化性质

• 沸点：
  537.5±60.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  78.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-Butyl 4-{2-[(cyclopropylmethyl)(methylsulfonyl) amino]phenyl}piperazinecarboxylate 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (2R)-2-Amino-3-(4-chlorophenyl)-1-(4-{2-[(cyclopropylmethyl) (methylsulfonyl)amino]phenyl}piperazinyl)propan-1-one
  参考文献：
  名称：

  Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides

  摘要：

  The biological activity for a set of melanocortin-4 receptor (MC4R) agonists containing a piperazine core with an ortho-substituted aryl sulfonamide is described. Compounds from this set had binding and functional activities at MC4R less than 30 nM. The most selective compound in this series was > 25,000-fold more potent at MC4R than MC3R, and 490-fold more potent at MC4R than MC5R. This compound also reduced food intake after oral dosing at 25, 50, and 100 mg kg(-1) in fasted mice. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.060
• 作为产物：
  描述：

  1-Boc-4-(2-氨基苯基)哌嗪 在 sodium hydride 、 N,N-二异丙基乙胺 作用下， 以 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 tert-Butyl 4-{2-[(cyclopropylmethyl)(methylsulfonyl) amino]phenyl}piperazinecarboxylate
  参考文献：
  名称：

  Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides

  摘要：

  The biological activity for a set of melanocortin-4 receptor (MC4R) agonists containing a piperazine core with an ortho-substituted aryl sulfonamide is described. Compounds from this set had binding and functional activities at MC4R less than 30 nM. The most selective compound in this series was > 25,000-fold more potent at MC4R than MC3R, and 490-fold more potent at MC4R than MC5R. This compound also reduced food intake after oral dosing at 25, 50, and 100 mg kg(-1) in fasted mice. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.060

文献信息

• Substituted piperazines and methods of use
  申请人：——

  公开号：US20030220324A1

  公开（公告）日：2003-11-27

  Selected substituted piperazine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选择的替代哌嗪化合物对于预防和治疗疾病，如肥胖等，具有有效性。该发明涵盖了新型化合物、类似物、前药和其药用盐，以及用于预防和治疗涉及黑素皮质素受体激活的疾病和其他疾病或病症的药物组合物和方法。该发明还涉及制备这类化合物的方法，以及在这些过程中有用的中间体。
• Melanocortin receptor agonists
  申请人：——

  公开号：US20040092507A1

  公开（公告）日：2004-05-13

  The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction. 1

  本发明涉及公式（I）的黑色素皮质素受体激动剂，其在肥胖症、糖尿病和男性和/或女性性功能障碍的治疗中有用。
• PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1368340A1

  公开（公告）日：2003-12-10
• US7291619B2
  申请人：——

  公开号：US7291619B2

  公开（公告）日：2007-11-06
• [EN] MELANOCORTIN RECEPTOR AGONISTS<br/>[FR] DERIVES DE PIPERAZINE AGONISTES DU RECEPTEUR DE LA MELANOCORTINE
  申请人：LILLY CO ELI

  公开号：WO2002059108A1

  公开（公告）日：2002-08-01

  The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction.